EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification

Ye Kuang, Yun Cheng, Jia Wang, Hongyan Li, Xianghong Cao, Yang Wang iD

Cancer Medicine · 2023-03 · 12 (6) · 7222-7233

DOI: 10.1002/cam4.5432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.11.2022. Verfasst von Ye Kuang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yan'An Hospital, Medical Laboratory, Kunming, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kunming Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. The long‐term use of sorafenib, a targeted drug for hepatocellular carcinoma, will lead to drug resistance, and patients are prone to cancer metastasis, the molecular mechanism of which is still unclear.

Methods

In our study, we constructed a sorafenib‐resistant hepatocellular carcinoma cell line (HepG2/Sora) and validated the resistance in vivo and in vitro. Transwell assays confirmed the invasion and migration abilities of cells. Colorimetric assays confirmed that the level of m6A methylation modification in cells. RT‐qPCR and Western blot assays confirmed that the expression levels of KIAA1429 in HepG2/Sora cells and tissues. The EMT related proteins were detected by Western blot assay.

Results

Transwell and Western blot assays confirmed that HepG2/Sora cells had higher invasion and migration abilities and showed EMT phenomena. Colorimetric assays confirmed that the level of m6A methylation modification was upregulated in HepG2/Sora cells. Transwell and Western blot assays confirmed that inhibiting m6A methylation in HepG2/Sora cells inhibited their invasion, migration ability and EMT phenomenon. RT‐qPCR and Western blot assays confirmed that the expression levels of KIAA1429 in HepG2/Sora cells and tissues was increased. Silencing KIAA1429 in HepG2/Sora cells inhibited their invasion, migration ability and EMT phenomenon. Finally, we found that the medium supernatant of sorafenib‐resistant HepG2/Sora cells induced vascular production of EA.hy926 cells, and silencing KIAA1429 inhibited this induction effect.

Conclusion

We suggest that KIAA1429 promotes sorafenib‐resistant hepatocellular carcinoma invasion, migration and EMT by mediating m6A methylation. KIAA1429 with its mediated m6A methylation may be a key factor for sorafenib‐resistant patients prone to cancer cell metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionMethylationSorafenibRNA-Binding Proteins

Stichwörter der Autor:innen

EMTKIAA1429hepatocellular carcinomam6A methylationsorafenib resistance

Substanzen

SorafenibVIRMA protein, humanRNA-Binding Proteins

Autor:innen und Institutionen

  • Yan'An Hospital, Medical Laboratory, Kunming, China.

ORCID-Profile: Yang Wang

Förderung

  • Kunming Medical University

Zitieren

APA

Kuang, Y., Cheng, Y., Wang, J., Li, H., Cao, X., & Wang, Y. (2023). KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification. Cancer Medicine, 12(6), 7222-7233. https://doi.org/10.1002/cam4.5432

Vancouver

Kuang Y, Cheng Y, Wang J, Li H, Cao X, Wang Y. KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification. Cancer Medicine. 2023;12(6):7222-7233. doi:10.1002/cam4.5432

BibTeX
@article{Kuang2023,
  author = {Kuang, Ye and Cheng, Yun and Wang, Jia and Li, Hongyan and Cao, Xianghong and Wang, Yang},
  title = {KIAA1429 mediates epithelial mesenchymal transition in sorafenib‐resistant hepatocellular carcinoma through m6A methylation modification},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {7222--7233},
  doi = {10.1002/cam4.5432}
}
Kostenlos starten →